CoChat

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U / mL in type 1 diabetes

Open access
Heise, Tim, Nørskov, Marianne, Nosek, Leszek, Kaplan, Kadriye, Famulla, Susanne, Haahr, Hanne L. · 2017 · Diabetes, Obesity and Metabolism
Cited by 118

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: To compare day‐to‐day and within‐day variability in glucose‐lowering effect between insulin degludec ( IDeg ) and insulin glargine 300 U / mL ( IGlar‐U300 ) in type 1 diabetes. Materials and methods: In this double‐blind, crossover study, patients were randomly assigned to 0.4 U /kg of IDeg or IGlar‐U300 once daily for two treatment periods lasting 12 days each. Pharmacodynamic variables were assessed at steady‐state from the glucose infusion rate profiles of three 24‐hour euglycaemic glucose clamps (days 6, 9 and 12) during each treatment period. Results: Overall, 57 patients completed both treatment periods (342 clamps). The potency of IGlar‐U300 was 30% lower than IDeg (estimated ratio 0.70, 95% confidence interval [ CI ] 0.61; 0.80; P < .0001). The distribution of glucose‐lowering effect was stable across 6‐hour intervals (24%‐26%) for IDeg , while IGlar‐U300 had greater effects in the first (35%) and last (28%) intervals compared with 6 to 12 hours (20%) and 12 to 18 hours (17%). Within‐day variability (relative fluctuation) was 37% lower with IDeg than with IGlar‐U300 (estimated ratio IDeg / IGlar‐U300 : 0.63, 95% CI 0.54; 0.73; P < .0001). The day‐to‐day variability in glucose‐lowering effect with IDeg was approximately 4 times lower than IGlar‐U300 (variance ratio IGlar‐U300 / IDeg : 3.70, 95% CI 2.42; 5.67; P < .0001). The day‐to‐day variability in glucose‐lowering effect assessed in 2‐hour intervals was consistently low with IDeg over 24 hours, but steadily increased with IGlar‐U300 to a maximum at 10 to 12 hours and 12 to 14 hours after dosing (variance ratios 12.4 and 11.4, respectively). Conclusion: IDeg has lower day‐to‐day and within‐day variability than IGlar‐U300 and a more stable glucose‐lowering effect, which might facilitate titration and enable tighter glycaemic control with a reduced risk of hypoglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12938

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 118

Metadata

Authors
Heise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S., & Haahr, H. L.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-04-23
Volume
19
Issue
7
Pages
1032-1039
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2603131458
Cited by
118
References
6
FWCI
13.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U / mL in type 1 diabetes. https://app.cochat.ai/papers/10.1111/dom.12938
The paper
Heise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S., & Haahr, H. L. (2017). Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U / mL in type 1 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12938

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.